2005
DOI: 10.2174/1566524054022576
|View full text |Cite
|
Sign up to set email alerts
|

Defining Criteria for Anti-Mannan Antibodies to Protect Against Candidiasis

Abstract: Prevention of hematogenously disseminated candidiasis and mucocutaneous disease, including Candida vaginitis, through immunological approaches is appealing for the following reason. A long-acting and safe vaccine that protects against both serotypes of Candida albicans and other important species, such as C. tropicalis and C. glabrata, should significantly reduce the incidence of various forms of candidiasis by these etiologic agents. Through extensive experimentation on protective responses in experimental an… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

1
38
0
2

Year Published

2006
2006
2017
2017

Publication Types

Select...
6
4

Relationship

0
10

Authors

Journals

citations
Cited by 55 publications
(41 citation statements)
references
References 66 publications
1
38
0
2
Order By: Relevance
“…According to our hypothesis, upon entry of yeast into the bloodstream, the events that take place within the ensuing minute or so are critical to determining where in the body C. albicans becomes associated. Rapid complement activation promoted by protective antibody will favor the subsequent association of the fungus with host phagocytic cells, whereas a delay in complement opsonization that occurs with nonprotective antibodies or with alternative complement pathway activation (52) may result in a higher probability of C. albicans becoming associated with nonphagocyte-associated host sites (11).…”
Section: Discussionmentioning
confidence: 99%
“…According to our hypothesis, upon entry of yeast into the bloodstream, the events that take place within the ensuing minute or so are critical to determining where in the body C. albicans becomes associated. Rapid complement activation promoted by protective antibody will favor the subsequent association of the fungus with host phagocytic cells, whereas a delay in complement opsonization that occurs with nonprotective antibodies or with alternative complement pathway activation (52) may result in a higher probability of C. albicans becoming associated with nonphagocyte-associated host sites (11).…”
Section: Discussionmentioning
confidence: 99%
“…There are two serotypes of C. albicans (19), and both are frequently recovered from asymptomatic individuals or candidiasis patients (1,5). To determine whether the role of mannan and glucan in complement activation is similar between these two serotypes, we extended the studies described above to CA1 cells, a serotype B of C. albicans that has been used for studies of murine anti-mannan antibody-mediated protection (9) and for characterization of complement activation (28,50,51). Similar to serotype A 3153A cells, CA1 cells treated with any one of the three chemical methods lost the ability to bind to anti-mannan antibodies, but CA1 cells subject to Smith degradation displayed glucan (data not shown).…”
Section: Fig 4 Kinetics Of C3 Activation and Binding By Glucan-dispmentioning
confidence: 99%
“…Both humoral and cell-mediated immunity are believed to play major roles in defense against Candida albicans (8). Cutler and co-workers (9 -11) have shown that glycoconjugates prepared from native antigen as well as monoclonal antibodies specific for this antigen afford protection in active and passive immunization protocols.…”
mentioning
confidence: 99%